Receive up-to-the-minute news updates on the hottest topics with NewsHub. Install now.

Alkermes' depression treatment fails to get FDA panel backing

November 2, 2018 12:05 AM
161 0

(Reuters) - An advisory panel to the U.S. Food and Drug Administration on Thursday voted against approving Alkermes Plc’s treatment for depression in patients with an inadequate response to standard antidepressant therapies.

The decision comes two days after FDA staff reviewers flagged abuse potential for the opioid-based depression treatment and raised questions on its efficacy.

Read more

Share in social networks:

Comments - 0